## Record investment for innovation in Europe The Novo Nordisk Foundation has announced an investment of up to €736 million (DKK 5.5 billion) in the BioInnovation Institute (BII), a Copenhagen-based institute focused on innovation in the life sciences and deep tech. This funding will enable BII to expand its activities into new strategic areas and support even more entrepreneurs and startups, with the aim of strengthening the innovation ecosystem in Denmark and Europe. BII supports startups with access to expertise, networks, infrastructure and funding of up to €3 million per project and €1.8 million per startup. ## Objectives and future strategies The new funding framework will cover the period from 2026 to 2035. The initiative aims to bridge the gap between the high-level scientific research produced in Europe and its translation into concrete innovations capable of creating jobs, stimulating economic growth and addressing the most urgent societal challenges. With a platform that has already helped create and develop more than 130 companies and attract more than €938 million in external funding, BII aims to scale its model to support European competitiveness. In the coming years, BII plans to significantly increase the number of startups supported annually, extending its reach to new scientific and technological fields such as artificial intelligence and quantum computing. ## Collaborations and perspectives BII has already established important collaborations with commercial and philanthropic partners, including initiatives with Ferring and the Gates Foundation to promote innovation in women's health, and partnerships with the Villum Foundation and the Lundbeck Foundation to support startups in Power-to-X technologies and brain disease treatment. The new funding will further strengthen BII's position as an attractive destination for investors and increase its ability to collaborate with academic institutions across Europe.